BCKDK inhibitors and/or degraders
AssigneePfizer Inc.
InventorsLeanne Marie Buzon, Kimberly O'Keefe Cameron, Kevin Francis Deboyace, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Shenping Liu, Luis Angel Martinez Alsina, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
Life of this patent
Estimating the term…
Abstract
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.
Claims16
A compound of Formula I
- wherein
- Z is S;
- A is
- X1 is CR11;
- each of R1, R3 and R4 are independently selected from H;
- R2 is fluoro;
- each of R5, R6, R7, R8, R9 and R11 are independently selected from H, halo, hydroxyl, amino, cyano, (C1-C4) alkyl, (C3-C6) cycloalkyl, (C1-C4) alkoxy, (C1-C4) fluoroalkyl, (C3-C6) fluorocycloalkyl, (C1-C4) fluoroalkoxy, or (C1-C4) alkyl-(C1-C4) alkoxy;
- and
- R10 is H, fluoro, chloro, cyano, or (C1-C4) alkyl;
- wherein at least one R5, R6, R7, R10 and R11 is other than H;
- or a pharmaceutically acceptable salt of said compound.
A compound, wherein the compound is:
- or a pharmaceutically acceptable salt thereof.
A compound, wherein the compound is
A compound, wherein the compound is:
- or a mixture thereof;
- or a pharmaceutically acceptable salt of said compound or mixture of compounds.
A compound, wherein the compound is
- or a mixture thereof.
Dependencies are inferred from the claim text.